BetterLife Pharma Inc. (BETRF) Form 6-K — Sep 15, 2026
BetterLife Pharma filed a 6-K carrying its information circular disclosure: for the fiscal year ended January 31, 2026, the company's three named executive officers — CEO Ahmad Doroudian ($300,000), COO Hooshmand Sheshbaradaran ($376,054) and CFO Moira Ong ($264,000) — drew roughly $940,000 in combined compensation excluding compensation securities.
Key figures
- Audit Fees FY2025
- 120322
- Audit Fees FY2026
- 125000
- Ltip Dilution Cap
- 10% of outstanding common shares fully diluted
- Year End Share Price
- $0.05
- Ceo Compensation FY2026
- 300000
- Ceo Termination Payment
- $600,000
- Cfo Compensation FY2026
- 264000
- Cfo Termination Payment
- $400,000
- Coo Compensation FY2026
- 376054
- Coo Termination Payment
- US$540,000
- Weighted Avg Exercise Price
- $0.10
- Equity Plan Securities Outstanding
- 55821182
- Compensation Settled In Shares April2025
- $851,000 settled via 8,506,372 common shares
- Securities Available For Future Issuance
- 6981786
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.